R&D | October 05, 2025
Takeda exits cell therapy research
Takeda will seek an external partner to leverage its cell therapy platform technologies
Takeda will seek an external partner to leverage its cell therapy platform technologies
The new site enables end-to-end production of viral vector gene therapies
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
IND application for EB-003 expected in early 2026
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Subscribe To Our Newsletter & Stay Updated
